跳到正文

ASTRAZENECA PLC

AZN · XNYS

CIK 901832fmd_1HNFSF1R12SXGA1SVS3Q0KKERG制造业 · 医药制剂模板: 标准

覆盖范围: 2015年1月01日 至 2025年12月31日,共 32 个期间

利润表 · 年度 · 百万 · USD
项目FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
营业总收入23,00222,46522,09024,38426,61737,41744,35145,81154,07358,739
营业成本4,1264,3184,9364,9215,29912,43712,3918,26810,20710,633
毛利润18,87618,14717,15419,46321,31824,98031,96037,54343,86648,106
研发费用5,8905,7575,9326,0595,9919,7369,76210,93513,58314,232
销售、一般及管理费用9,41310,23310,03111,68211,29415,23418,41919,21619,97719,933
营业利润4,9023,6773,3872,9245,1621,0563,7578,19310,00313,743
利息费用1,3841,5081,4191,4321,3061,3001,3461,6261,7421,694
税前利润3,5522,2271,9931,5483,916(265)2,5016,8998,69112,402
所得税费用146(641)(57)321772(380)(792)9381,6502,169
持续经营净利润3,4062,8682,0501,2273,1441153,2935,9617,04110,233
净利润3,4993,0012,1551,3353,1961123,2885,9557,03510,225
归属于普通股股东的净利润3,4993,0012,1551,3353,1961123,2885,9557,03510,225
ASTRAZENECA PLC (AZN) 财务报表 · FinancialMD